Press Releases

• May 7, 2018
  

  C-Path Receives COA Qualification from FDA for the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ)

    TUCSON, Ariz. – May 7, 2018 — Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium announces its second clinical outcome assessment (COA) qualification from the US Food and Drug Administration (FDA). The qualification of the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) for exploratory use represents another major milestone for the PRO Consortium and,...
• April 16, 2018
  

  Helmsley Charitable Trust Awards Critical Path Institute a Grant to Focus on Crohn’s Disease Biomarkers

  Tucson, AZ, and New York, NY – April 16, 2018 — The Leona M. and Harry B. Helmsley Charitable Trust has awarded Critical Path Institute (C-Path) a grant to support a Crohn’s disease biomarker pre-consortium. The pre-consortium will identify unmet needs for the use of biomarkers in developing new treatments for people with Crohn’s disease. Currently,...
• March 28, 2018
  

  C-Path and CHDI launch consortium to accelerate development of Huntington’s disease therapies

        Tucson, AZ, and New York, NY – March 28, 2018 – The Critical Path Institute (C-Path), together with CHDI Foundation, Inc. (CHDI), today announced the official launch of C-Path’s Huntington’s Disease Regulatory Science Consortium (HD-RSC). In addition to these cofounders, the consortium also includes more than 20 different member organizations, including industry partners,...
• March 24, 2018
  

  Global Health Partners Accelerate Uptake of Genetic Sequencing for Surveillance And Diagnosis Of Drug-Resistant Tuberculosis

        WHO adopts ReSeqTB as bioinformatics platform for TB surveillance, enabling the global scale-up of culture-free, drug-resistant Mycobacterium tuberculosis surveillance programs based on sequencing technologies Renewed funding from the Bill & Melinda Gates Foundation has been applied for to support FIND, C-Path, and WHO to take ReSeqTB to the next level as part...
• January 22, 2018
  

  Critical Path Institute Receives Regulatory Support for Liver Injury Biomarker

  Tucson, AZ — January 22, 2018 — Critical Path Institute (C-Path) announced today that the European Medicines Agency (EMA) has issued a Letter of Support for measurement of glutamate dehydrogenase (GLDH) as a biomarker of hepatocellular liver injury. The letter was awarded to C-Path’s Predictive Safety Testing Consortium (PSTC) and Duchenne Regulatory Science Consortium (D-RSC)...